What is the Purpose of this Study?
-Primary Objective: This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also known as ARRY-134) as a single agent and in combination with other targeted agents in participants with advanced solid tumors. PF-07799544 (also known as ARRY-134) is a highly selective brain-penetrant small molecule inhibitor of MEK1/2 that is being investigated in participants with advanced solid tumors. -Secondary Objective To characterize the single and multiple-dose PK of PF-07799544 as a single agent. To evaluate preliminary antitumor activity of PF-07799544 as a single agent.
Eligibility
- * Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation
- * Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
- * For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma
- * For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS